|
H. Erich Wichmann answers a few questions about this month's
new hot paper in the field of Social Sciences, general.
From
•>>March 2006
Field:
Social Sciences, general
Article Title: KORA - A research platform for population based health research
Authors: Holle, R;Happich, M;Lowel, H;Wichmann,
HE;MONICA KORA Study Grp
Journal: GESUNDHEITSWESEN
Volume: 67
Issue:
Page: :S19-S25
Year: Suppl. 1 AUG 2005
* GSF, Forschungszentrum Umwelt & Gesundheit, Inst Gesundheitsokon & Management Gesundheitswese, IGM, Ingolstadter Landstr 1, D-85758 Neuherberg, Germany.
* GSF, Forschungszentrum Umwelt & Gesundheit, Inst Gesundheitsokon & Management Gesundheitswese, IGM, D-85758 Neuherberg, Germany.
* GSF, Forschungszentrum Umwelt & Gesundheit, Inst Epidemiol, D-85758 Neuherberg, Germany.
|
Why
do you think your paper is highly cited?
|

“...KORA-gen provides a proof of principle that existing population-based studies can successfully be used for genetic research.”
|
|
The paper describes the biobank KORA-gen which is based on an
epidemiological cohort. This cohort has recently also been made
available for genetic research by external partners. Meanwhile,
KORA-gen is frequently used and has contributed to more than 70
genetic-epidemiological studies during the last three years. These
are case-control studies, studies with quantitative traits, several
meta-analyses, and comparisons with other populations.
To me, the paper has primarily been frequently cited for two main
reasons: (i) because researchers are interested in the concept of
opening local resources for the scientific community, and (ii) as a
reference in publications where data from KORA-gen has been used.
Does
it describe a new discovery or a new methodology that's useful to
others?
KORA-gen is a new resource for genetic epidemiological studies.
The objective is to provide access to DNA samples and phenotypic
data from about 18,000 participants with mortality and morbidity
follow-up for up to 20 years. These are adults from the general
population who participated in four surveys of 4,000-5,000 subjects
each. The individuals were from 25 to 74 years of age and randomly
selected from a population of 600,000 citizens. Furthermore, data
from two follow-up investigations will be available shortly,
covering about 6,000 participants re-investigated after 7-10 years.
Meanwhile, the oldest age group is now above 90 years old. In the
underlying studies a wealth of information on sociodemography,
environmental factors, smoking, nutrition, alcohol consumption,
general medical history, and various laboratory parameters has been
collected. Genomic DNA, serum plasma, and urine are available from
most of the participants and also available are the immortalized
cell lines from 1,500 persons.
The KORA-gen infrastructure covers aspects of study design,
sampling, and matching, of DNA-handling and the determination of
genetic markers, and also of data structures and formats. This is
supported by Internet-based information and by providing competent
individual counseling and assistance. A Web
portal has been implemented to deliver information about available
data and biosamples, rules about data ownership and data access, and
the process of applying for a collaborative project. All genotypes are
fed back into the common database for permanent storage.
The gradual accumulation of this genotypic information will add
significant value to the overall dataset. In maintaining and
administrating the central KORA-gen data base, the GSF National
Research Center for Environment and Health acts as trustee. For all
genetic and phenotype data items, ownership is given to those
scientists who provided the data. Access to these data sets for
scientific analyses is only granted with the permission of the data
owners—based on the given rules of ethics and confidentiality, as
well as the quality criteria.
Could
you summarize the significance of your paper in layman's terms?
In KORA-gen important prerequisites for successful
genetic-epidemiological research are fulfilled: (i) sufficiently
large number of participants, (ii) well-characterized disease and
intermediate phenotypes, (iii) well-recorded information about
environmental factors and exposures, and (iv) the availability of
biosamples.
Due to a broad, standardized phenotyping, it was possible to find
or replicate genetic associations with several complex diseases and
quantitative traits within KORA-gen. Examples were found of allergic
diseases, cardiovascular diseases, diabetes, body-mass index (BMI),
ECG parameters. One study on BMI has just been accepted for
publication by Science.
We have started a KORA 500K Chip Project with several partners.
In this project, 1,500 subjects who have participated in the basic
survey and the follow-up investigation after 10 years will be
genotyped by 500K chips. In this genome-wide approach, we will
analyze several endpoints, such as type-2 diabetes, metabolic
syndrome, hypertension, BMI, QT interval—the period that extends
from the beginning of ventricular depolarization until the end of
ventricular repolarization—left ventricular hypertrophy (LVH),
inflammatory and lipid parameters, as well as the addiction to
nicotine.
Since this sample of 1,500 persons is also representative for the
general population, it can be used as a control group for
case-control studies. This will drastically reduce the costs for
genotyping, since the genotypes of the controls are already in
place.
How
did you become involved in this research, and were any problems
encountered along the way?
We have performed classical epidemiological research since
1984/85, first within the WHO MONICA project (Monitoring of trends
and determinants in cardiovascular disease) and then in the KORA
project (Cooperative health research in the region of Augsburg). We
started with cardiovascular questions and then expanded these
activities to focus on other diseases. We established a common
database and a trustee system for the mutual use of the data,
co-financed by several partners. Since this system worked so
efficiently and generated a large number and variety of publications—in
total about 400 papers through the end of 2005—we thought of
offering it to a broad spectrum of users who are interested in
genetic research.
However, before this could be realized, questions of how to deal
with data ownership, ethical issues, and questions of
confidentiality needed to be resolved. In 2005, a Web
site was established to
facilitate the use of this valuable resource. Meanwhile KORA-gen is
well accepted and frequently used by German researchers as well as by
international scientists.
What
are the social or political implications of your research?
KORA-gen demonstrates that existing
population-based studies can successfully be used for genetic
research. KORA-gen is based on the Cooperative Health Research
Initiative in the region of Augsburg near Munich in Southern
Germany. It is hosted and funded by the GSF-National Research Center
for Environment and Health, as part of the Helmholtz Association.
There is co-financing from the German National Genome Research
Network (NGFN) and from several collaborators from among
universities and research centers. KORA-gen is member of the Public
Population Project in Genomics (P³G ).
Prof. dr. Dr. H. Erich Wichmann
Institut für Epidemiologie am GSF-Forschungszentrum für Umwelt und
Gesundheit
Neuherberg, München, Germany
Related
Links:
All external sites will open in a new browser.
The Thomson Corporation and esi-topics.com does not endorse external sites.
|
ESI Special Topics,
March 2006
Citing URL - http://www.esi-topics.com/nhp/2006/march-06-HErichWichmann.html
|
|